Bronkhorst opens new UK premises
Move to Newmarket offers scope for expansion
A wholly owned subsidiary of Bronkhorst High-Tech BV of Holland, the company was established in Sawston, Cambridgeshire in 2002, since when it claims to have increased turnover by 800%.
Having outgrown its original headquarters, the company has relocated to Newmarket in order to have room for future expansion and gain access to the local pool of skilled labour. There are plans to double the workforce within the next five years.
To mark the occasion, Councillor Mick Jeffrys, the Mayor of Newmarket, performed the official opening. Special guests included the joint founders and co-owners of Bronkhorst, Teus Bruggemann and Wybren Jouwsma, who have invested substantially in growing the UK operation and have a policy of investing around 15% of group annual turnover on r&d.
Bronkhorst UK’s managing director Andrew Mangell, said: ‘We have grown rapidly in terms of both sales revenue and staff numbers, even maintaining an upward trend during the recession, and our new Newmarket base gives us more valuable floorspace, good links with the travel network and a superb quality of environment.’
Bronkhorst claims to supply virtually every customer sector in the UK, taking in laboratory, university, industrial, pilot plant and hazardous area applications.
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer